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LETTERS TO THE EDITOR
Regarding “A randomized trial of carotid artery
stenting with and without cerebral protection”
We read with interest the report from the randomized trial of
carotid artery stenting (CAS) with and without cerebral protection
(CP), by Barbato et al. In this article, the authors aimed to test the
hypothesis that the use of filter protection would decrease the
percentage of cerebral embolic events, but at the end they reported
a relatively high complication rate for both randomized groups
(stroke at 30 days  11%).
Although CAS has developed rapidly over the last decade as a
minimally invasive alternative to carotid endarterectomy (CEA),
the optimal carotid revascularization strategy still remains a con-
troversial issue, and articles like this can prompt debate.
While we believe that the utility of CP does not need to be
demonstrated by a randomized trial, in our opinion, the way that
this trial was designedmeant that it could not effectively investigate
the value of filters. In order to study what really happens with or
without CP, the study design should have used transcranial Dopp-
ler to analyze the number of hits that occurred during the advance-
ment and deployment of the stent and the post-dilatation maneu-
vers in the unprotected group, as well as during the filter
deployment and retrieval maneuvers in the protected group.
By analyzing the occurrence of new embolic lesions by diffusion-
weighted magnetic resonance imaging (DW-MRI) 24 hours after
stenting, the authors did not focus on whether the events occurred
during the procedure (in any phase ofCAS: archmaneuvers, common
carotid engagement, stenting, ballooning, etc.) or later in the clinical
course. They even neglected to specify whether the four strokes were
intra- or post-procedural complications. Did these neurological
events occur during the arch maneuvers for carotid engagement1 (as
the cerebral contralateral lesions shown in 19%of patients atDWMRI
would seem to reveal) or in the early post-operative period? Both
hypotheses make it difficult to blame the use or non-use of CP.Many
microemboli can occur in the first hours after CAS and are probably
related to the composition of the treated plaque and to the scaffolding
property of the stent.2 In this study, no plaque characteristics were
reported and this could have distorted the results.
Another comment regards the low recruitment rate. Over two
years, only 35 patients were enrolled, while 225 patients (86.5%)
were excluded. What was the rate of patients who refused to give
consent to be randomized for a protected versus unprotected CAS?
Is the benefit of CP so intuitive as to be clear also to the
patients?
In conclusion, we agree with the authors that “the lack of
major strokes in the CP group may argue that at least large emboli
are captured” but their “numbers are too small to offer such a
reassuring statement,” however, we also think that these numbers
(without the exact timing of the complications and without related
plaque composition) are also too small to offer any definite state-
ment regarding the utility of CP.
Carlo Setacci, MD
Gianmarco de Donato, MD
Vascular and Endovascular Surgery Unit
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Reply
We readwith interest the letter to the editor fromDrDeDonato.
We certainly expected our study to be controversial and generate a
number of comments, because the value of filter cerebral protection
(CP) has been accepted as intuitivewith no reasonable justification for
any testing as the letter suggests. We disagree with that position,
because significant evidence suggests the opposite. As an example the
ARCHeR trial reported the lowest stroke rates in the first phase of the
study without any CP, with adverse events increasing with the intro-
ductionofCP in the second two arms, evenwith the added experience
of the operators.1 Themedical community has accepted the benefit of
filters without any discussion or evaluation, which has negatively
influenced the acceptance of patients to be enrolled in this trial as
suggested by the letter.
We differ significantly with the authors of the letter on whether
our trial design would have provided information about the value of
CP had the trial reached its target enrollment. A randomized trial is
the perfect vehicle for this determination, because all other confound-
ing factors would be expected to be equivalent between the two arms,
except forCP.The timingof thesemicroemboliwouldbe irrelevant in
a randomized trial design, because specifically the arch manipulation
and the postoperative events should be independent of CP and be
present to an equal degree between groups. Adding transcranial
doppler (TCD) evaluation to determine timing would have to be
extended for days, and the information is already available.Moreover,
the multitude of embolic signals on TCD does not necessarily equate
with brain tissue damage as DW MRI does. MacDonald2 did use
TCD in a study very similar to ourswithnearly identical results onDW
MRI; he also identified more hits during the procedure in patients
with CP. All the clinical events in our study occurred during the
procedure.
Since the development of our protocol in late 2002, many
patient and plaque characteristics have been identified to increase
the risk of carotid artery stenting (CAS), including age and plaque
composition but also arch anatomy, and more recently anatomic
characteristics of the lesion such as length and ostial location.3 We
stratified our randomization by symptomatic status, which is the
most significant predictor of adverse events known at the time, but
for obvious reasons not with all other factors identified since.
Although plaque echolucency has become of late a known predic-
tor of outcomes, it is also associated with symptomatic status that
was evenly randomized.
We have acknowledged that our study was underpowered and
does not offer conclusive proof as to the value or lack thereof of
CP. The study, however, does point to a possible downside of
filters, and a blanket insistence on their use in every case may be
detrimental to patient outcomes.
Michel S. Makaroun, MD
University of Pittsburgh
Pittsburgh, Pa
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